AQUALUNG
27.4.2021 11:02:13 CEST | Business Wire | Press release
Aqualung , the leading global designer and manufacturer of dive and water sports gear, today announced the launch of its all new XSCAPE collection. Featuring a 100 percent neoprene-free wetsuit and a rash guard made from sustainable materials, the XSCAPE line is designed for a variety of water activities and reflects Aqualung’s commitment to innovation, ocean discovery and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005227/en/
Made with Yulex® eco-friendly natural rubber and ultra-stretch fabric, the 4/3mm XSCAPE wetsuit provides enhanced comfort for diving in warm waters or above surface activities in colder temperatures, and can be used for scuba diving, snorkeling, freediving, paddling or a variety of other water sports. The flexible and lightweight XSCAPE wetsuit, available in a red and olive design for men and a tropical-inspired print for women, connects consumers to nature and the natural materials the collection is made from. The suit also features Powertex knee pads, recycled, quick-drying fleece around the torso area to provide additional warmth and comfort, and a reusable mesh bag for storage after use or collecting trash from the beach or water.
“The XSCAPE collection continues Aqualung's legacy in innovation, and their tireless work to create the most forward thinking and eco-conscious dive company in the world,” said Aqualung global ocean ambassador Philippe Cousteau Jr., the grandson of one of Aqualung’s original founders, Captain Jacques-Yves Cousteau. “We all have the power to change the world with the choices we make, and the XSCAPE sets the new standard for wetsuits and rash guards that are stylish, functional and sustainable.”
The new collection’s long-sleeve rash guard for men and women, and matching women’s leggings, offer maximum comfort and breathability and can be used above or below the surface. All rash guards and leggings feature UV protection and are made with polyester fabric sourced from recycled plastic bottles. The entire XSCAPE line comes in plastic-free packaging with hangtags made from recycled cardboard.
“Our aim was to design the ultimate eco-friendly wetsuit that could be used for all kinds of water sports,” said Laurent Boury, Senior Vice President of Brands at Aqualung Group. “Aqualung is committed to using environmentally-friendly materials and processes whenever possible to help reduce our carbon footprint, and we made design choices to ensure the XSCAPE collection was as sustainable as possible.”
“The collection name, XSCAPE, is meant to evoke the feeling of freedom and the quest for wonder that surround exploration, travel and Aqualung’s storied history, including the first ‘aqua-lung’ created by Captain Jacques-Yves Cousteau and engineer Emile Gagnan that made underwater exploration possible,” added Boury.
The XSCAPE collection is available at authorized Aqualung retailers. Inventory may vary by region. To learn more, please visit www.aqualung.com .
About Aqualung Brand
Aqualung, part of the Aqualung Group, is the leading global designer and manufacturer of dive and water sports gear. Now available in more than 100 countries around the world, Aqualung pioneered the creation of modern diving equipment when Captain Jacques-Yves Cousteau teamed with engineer Emile Gagnan in 1943 to develop the first “aqua-lung,” making underwater exploration possible. Aqualung is committed to providing sustainable, innovative, reliable, and easy-to-use products that allow adventure seekers to enjoy responsible water exploration and continues to set the industry standard for water sports equipment in technology, comfort, safety and design. For more information, visit www.aqualung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005227/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom